Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.35 |
| ▸ | CPT2 | P23786 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 3/20 | 0.32 |
| ▸ | LDHA | P00338 | 2/20 | 0.30 |
| ▸ | LDHB | P07195 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL468400 | 0.79 | ALDH1A1 (0.48) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL28066136 | 0.77 | ALDH1A1 (0.39) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL5973422 | 0.74 | ALDH1A1 (0.38) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL1521278 | 0.74 | HMGCR (0.43) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Glycolic Acid SCHEMBL15708368 | 0.72 | ALDH1A1 (0.48) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL349827 | 0.72 | GLRA1 (0.45) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL16374685 | 0.71 | ALDH1A1 (0.45) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL26361 | 0.71 | ALDH1A1 (0.45) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL10589741 | 0.71 | — | — | |
| SCHEMBL11803129 | 0.71 | ALDH1A1 (0.60) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011088837-A1 | TREATMENT OF CARDIAC CONDITIONS | ZEALAND PHARMA A/S (DK) | 2011-07-28 | — | — | WO | claimed |
| EP-2970511-B1 | INSULIN-INCRETIN CONJUGATES | UNIV INDIANA RES & TECH CORP (US) | 2020-09-30 | — | — | EP | disclosed |
| US-10730923-B2 | Glucagon/GLP-1 receptor co-agonists | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-08-04 | — | — | US | disclosed |
| US-10696726-B2 | Insulin-incretin conjugates | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-10683334-B2 | Aqueously soluble and chemically stable glucagon peptides | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-06-16 | — | — | US | disclosed |
| EP-3206710-B1 | INCRETIN-INSULIN CONJUGATES | UNIV INDIANA RES & TECH CORP (US) | 2020-05-06 | — | — | EP | disclosed |
| CN-105324397-B | Insulin-incretin conjugates | 印第安纳大学研究及科技有限公司 | 2020-01-14 | — | — | CN | disclosed |
| US-20190290772-A1 | GLUCAGON-LIKE PEPTIDE-1-T3 CONJUGATES | UNIV INDIANA RES & TECH CORP (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190218268-A1 | AQUEOUSLY SOLUBLE & CHEMICALLY STABLE GLUCAGON PEPTIDES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2019-07-18 | — | — | US | disclosed |
| US-20190127433-A1 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | UNIV INDIANA RES & TECH CORP (US) | 2019-05-02 | — | — | US | disclosed |
| US-20110166062-A1 | GIP-BASED MIXED AGONISTS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
| WO-2011075393-A2 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2011-06-23 | — | — | WO | disclosed |
| EP-2307037-A1 | GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS | Indiana University Research and Technology Corporation (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-2300037-A2 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | Indiana University Research and Technology Corporation (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2300035-A2 | GIP-BASED MIXED AGONISTS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY | Indiana University Research and Technology Corporation (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010148089-A1 | GIP RECEPTOR-ACTIVE GLUCAGON COMPOUNDS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010071807-A1 | AMIDE BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010011439-A2 | GIP-BASED MIXED AGONISTS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009155258-A2 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009155257-A1 | GLUCAGON ANALOGS EXHIBITING ENHANCED SOLUBILITY AND STABILITY PHYSIOLOGICAL PH BUFFERS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290772-A1 | GLUCAGON-LIKE PEPTIDE-1-T3 CONJUGATES | GLP1R, GIPR, GCGR | ALDH1A1 2137/4885HMGCR 2084/4885CHRM1 1191/4885 |
| US-20190127433-A1 | GLUCAGON/GLP-1 RECEPTOR CO-AGONISTS | GLP1R, GCGR, GIPR | ALDH1A1 4327/4885HMGCR 3915/4885CHRM1 2285/4885 |
| US-10730923-B2 | Glucagon/GLP-1 receptor co-agonists | GLP1R, GCGR, GIPR | ALDH1A1 4327/4885HMGCR 3915/4885CHRM1 2285/4885 |
| US-20190218268-A1 | AQUEOUSLY SOLUBLE & CHEMICALLY STABLE GLUCAGON PEPTIDES | IAPP, GLP1R, GCG | ALDH1A1 4040/4885HMGCR 3755/4885CHRM1 1890/4885 |
| US-10696726-B2 | Insulin-incretin conjugates | GLP1R, IAPP, GIPR | ALDH1A1 3209/4885HMGCR 2508/4885CHRM1 4110/4885 |
| US-20110166062-A1 | GIP-BASED MIXED AGONISTS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY | GIPR, GLP1R, GCGR | ALDH1A1 4437/4885HMGCR 2150/4885CHRM1 2625/4885 |
| US-10683334-B2 | Aqueously soluble and chemically stable glucagon peptides | IAPP, GLP1R, GCG | ALDH1A1 4258/4885HMGCR 3724/4885CHRM1 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.